Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[SMANCS/lipiodol]

¹Dept. of Microbiology, Kumamoto University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|May 1, 1994

Summary

This summary is machine-generated.

SMANCS, a polymer-conjugated drug, shows high tumor accumulation and diagnostic imaging benefits for liver cancer treatment. This innovative therapy, SMANCS/Lipiodol, offers a favorable safety profile with minimal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hydroxyl radical production by H2O2 plus Cu,Zn-superoxide dismutase reflects the activity of free copper released from the oxidatively damaged enzyme.

The Journal of biological chemistry·1992

Same author

Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture.

Journal of cardiovascular pharmacology·1992

Same author

Inhibition of mite protease (Df-protease) with protease inhibitors.

Biochemistry international·1992

Same author

[Pharmacokinetic and clinical studies of cefprozil fine granules in children].

The Japanese journal of antibiotics·1992

Same author

[A case of primary alveolar hypoventilation syndrome with a good response to nocturnal low-flow oxygen inhalation and negative pressure ventilation].

Nihon Kyobu Shikkan Gakkai zasshi·1992

Same author

Microvasculature of normal and hydropic labyrinth.

Scanning microscopy·1992

Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

See all related articles

Area of Science:

Oncology
Polymer Chemistry
Drug Delivery Systems

Context:

Hepatocellular carcinoma (HCC) presents a significant global health challenge.
Effective and targeted drug delivery remains crucial for improving cancer treatment outcomes.
SMANCS represents a novel approach in polymer-drug conjugate development.

Purpose:

To introduce SMANCS (poly(styrene-co-maleic acid) antineoplastic) as a pioneering polymer-conjugated drug.
To evaluate the efficacy and safety of SMANCS/Lipiodol in treating hepatoma.
To explore the diagnostic and therapeutic advantages of SMANCS/Lipiodol.

Summary:

SMANCS is the first commercial polymer-conjugated drug, linking neocarzinostatin with poly(styrene-co-maleic acid) half-butylate.
Administered arterially in Lipiodol, SMANCS/Lipiodol achieves a high tumor/blood ratio (>1,000) and provides excellent X-ray contrast for precise dosing.

Related Experiment Videos

Phase I/II studies led to its 1993 approval in Japan for hepatoma treatment, with ongoing exploration for other cancers.

Impact:

SMANCS/Lipiodol demonstrates significant therapeutic response rates (up to 90% at 12 months for Grad IV retention).
The treatment exhibits a favorable safety profile, with fever as the primary transitory side effect and no observed bone-marrow, renal, or hepatic toxicity.
Its diagnostic capabilities enhance treatment planning and monitoring, offering a dual advantage in cancer therapy.